Supercharge Your Innovation With Domain-Expert AI Agents!

CLEC18A protein-based medicine for preventing and inhibiting inflammatory response of organism and application of CLEC18A protein-based medicine

A CLEC18A, inflammatory response technology, applied in the field of biomedicine, can solve problems such as unreported effects, achieve the effects of preventing and inhibiting inflammatory effects, reducing potential damage and side effects, and reducing damage

Pending Publication Date: 2022-07-15
JIANGSU CONCORD BIOTECHNOLOGY CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As the only exocrine molecule in this family, the role of CLEC18A in other diseases has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CLEC18A protein-based medicine for preventing and inhibiting inflammatory response of organism and application of CLEC18A protein-based medicine
  • CLEC18A protein-based medicine for preventing and inhibiting inflammatory response of organism and application of CLEC18A protein-based medicine
  • CLEC18A protein-based medicine for preventing and inhibiting inflammatory response of organism and application of CLEC18A protein-based medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Recombinant human CLEC18A (CUSABIO, Cat. No. CSB-EP005521HU) can significantly reduce the production of inflammatory factors TNFα and IL-6 in human peripheral blood mononuclear cells induced by LPS, a cell wall component of E. coli.

[0023] Method and model establishment: Peripheral blood was drawn from healthy people, peripheral blood mononuclear cells were isolated, and plated in 24-well cell culture plates, 5 × 10 cells per well. 5 cell. Grouping: control group with medium, LPS group with 100ng / ml LPS, treatment group with 100ng / ml LPS first, 2 hours later, 20ng / ml, 50ng / ml and 100ng / ml recombinant human CLEC18A were added respectively. After 6 hours, the cell culture supernatant was taken, and the concentrations of TNFα and IL-6 were detected by ELISA. The result is as figure 1 shown, recombinant human CLEC18A was found to significantly attenuate LPS-induced production of TNFα and IL-6 in peripheral blood mononuclear cells.

Embodiment 2

[0025] Treatment of LPS-induced acute lung injury in mice by recombinant mouse CLEC18A (CUSABIO, Cat. No. CSB-YP759740MO).

[0026] 8-10-week-old C57BL / 6 mice were randomly divided into 3 groups with 4 mice in each group. All mice were anesthetized by sevoflurane inhalation before the experiment.

[0027] Prevention experiment: mice in the control group were intubated with 100 μl PBS; LPS group was intubated with 100 μl LPS; mice in the prevention group were intraperitoneally injected with 1 ng / g of recombinant mouse CLEC18A for 2 hours and then intratracheally injected with LPS.

[0028] Treatment experiment: the control group and the LPS group are the same as above. 2 hours after intratracheal injection of LPS in the treatment group, 2ng / g recombinant mouse CLEC18A was intraperitoneally injected.

[0029] Results: After 6 hours, the mice were washed with bronchoalveolar lavage fluid (BALF), and CD11b in BALF was detected by flow cytometry. high Gr-1 high Neutrophils were ...

Embodiment 3

[0032] Treatment of S. aureus-induced pulmonary infection by recombinant mouse CLEC18A.

[0033]Methods and model establishment: C57BL / 6 mice aged 8-10 weeks were randomly divided into 3 groups with 4 mice in each group. All mice were subjected to sevoflurane inhalation anesthesia before experiments. Grouping: mice in the control group were slowly inhaled with 100 μl of PBS, and mice in the bacterial group were inhaled with 100 μl of S. aureus dissolved in PBS (5×10 7 ). The mice in the treatment group were intraperitoneally injected with 1 ng / g CLEC18A of recombinant mice 4 hours after S. aureus inhalation.

[0034] Judgment of results: BALF of mice was washed after 24 hours, and CD11b in BALF was detected by flow cytometry high Gr-1 high Neutrophils were counted and the concentrations of TNFα and IL-6 in BALF were detected by ELISA. Lung tissue for pathological HE staining. Alanine transaminase (ALT) and aspartate aminotransferase (AST) were detected in mouse serum to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicine, and relates to a medicine application of lectin family molecule CLEC18A protein, in particular to a medicine for preventing and inhibiting body inflammatory response based on CLEC18A protein and an application. According to the medicine for preventing and inhibiting the inflammatory reaction based on the CLEC18A protein, the effective ingredient of the medicine contains the CLEC18A protein. The invention has the following advantages: 1, the CLEC18A can alleviate injury caused by inflammation by inhibiting immune response of the body, and plays a role in preventing and inhibiting inflammation; 2, the anti-inflammatory effect on gram-negative bacterium infection and gram-positive bacterium infection is achieved; 3, the composition has an anti-inflammatory effect on local infection and systemic bacterial infection; and 4, the CLEC18A is a protein generated by an inflammation-induced body, is one of important components in a negative feedback regulation and control inflammation mechanism of the body, and has smaller potential damage and side effects on a human body.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to the pharmaceutical application of the lectin family molecule CLEC18A protein, in particular to a CLEC18A protein-based medicine for preventing and inhibiting the body's inflammatory response and its application. Background technique [0002] Bacteria can be divided into Gram-negative bacteria (such as Escherichia coli, etc.) and Gram-positive bacteria (such as Staphylococcus aureus, etc.), which are an indispensable part of the human living environment and an important part of the entire ecosystem. A large number of bacteria exist on the surface of the human body and in the body cavities normally open to the outside world in the human body, such as the oral cavity, nasal cavity, rectum, and urogenital tract. These bacteria are normally harmless or even beneficial to the human body. Lactobacillus in the vagina plays an important role in maintaining the stability of the local ecosystem and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P29/00A61P31/04
CPCA61K38/1709A61P29/00A61P31/04
Inventor 张燕
Owner JIANGSU CONCORD BIOTECHNOLOGY CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com